Pure Global
NCT06384755

Honest Open Proud for Psychotic and Bipolar Disorder in Norway

Evaluation of a Norwegian Adaptation of the Honest Open Proud Program for Adults With Psychotic and Bipolar Disorders in an Outpatient Setting
Oslo University Hospital·ClinicalTrials.gov·behavioralRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Psychotic Disorders,Bipolar Disorder,Disclosure
Drug/Device/Intervention
Honest Open Proud program
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Oslo University Hospital
Location
Oslo,Oslo, Norway
Timeline & enrollment
Phase
N/A
Start date
Apr 20, 2024
End date
Dec 31, 2026
Enrollment
40 participants
Primary outcome

Stigma Stress Scale (Rüsch, Corrigan, Wassel et al., 2009; Rüsch, Corrigan, Powell et al., 2009)

Summary

The purpose of this pilot study is to evaluate the feasibility, acceptability and efficacy of
 a Norwegian adaptation of the group-based intervention 'Honest Open Proud' among adults with
 psychotic and bipolar disorders in an outpatient setting.

ICD-10 classifications
Bipolar affective disorder, current episode severe depression with psychotic symptomsBipolar affective disorder, current episode manic with psychotic symptomsBipolar affective disorder, current episode severe depression without psychotic symptomsBipolar affective disorder, current episode manic without psychotic symptomsMania with psychotic symptoms
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06384755
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06384755 through Pure Global AI's free database. This phase not specified trial is sponsored by Oslo University Hospital and is currently Recruiting. The study focuses on Psychotic Disorders,Bipolar Disorder,Disclosure. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.